| Literature DB >> 26872005 |
Melinda Craike1, Cadeyrn J Gaskin1, Kerry S Courneya2, Steve F Fraser3, Jo Salmon3, Patrick J Owen3, Suzanne Broadbent4, Patricia M Livingston5.
Abstract
Understanding the factors that influence adherence to exercise programs is necessary to develop effective interventions for people with cancer. We examined the predictors of adherence to a supervised exercise program for participants in the ENGAGE study - a cluster randomized controlled trial that assessed the efficacy of a clinician-referred 12-week exercise program among men treated for prostate cancer. Demographic, clinical, behavioral, and psychosocial data from 52 participants in the intervention group were collected at baseline through self-report and medical records. Adherence to the supervised exercise program was assessed through objective attendance records. Adherence to the supervised exercise program was 80.3%. In the univariate analyses, cancer-specific quality of life subscales (role functioning r = 0.37, P = 0.01; sexual activity r = 0.26, P = 0.06; fatigue r = -0.26, P = 0.06, and hormonal symptoms r = -0.31, P = 0.03) and education (d = -0.60, P = 0.011) were associated with adherence. In the subsequent multivariate analysis, role functioning (B = 0.309, P = 0.019) and hormonal symptoms (B = -0.483, P = 0.054) independently predicted adherence. Men who experienced more severe hormonal symptoms had lower levels of adherence to the exercise program. Those who experienced more positive perceptions of their ability to perform daily tasks and leisure activities had higher levels of adherence to the exercise program. Hormonal symptoms and role functioning need to be considered when conducting exercise programs for men who have been treated for prostate cancer.Entities:
Keywords: Adherence; exercise; neoplasms; physical activity; prostatic neoplasms
Mesh:
Substances:
Year: 2016 PMID: 26872005 PMCID: PMC4864808 DOI: 10.1002/cam4.639
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Behavior and psychosocial factors associations with adherence: univariate analyses
|
|
|
| |
|---|---|---|---|
| Memorial Anxiety Scale | 52 | −0.14 | 0.34 |
| CES‐D | 52 | −0.05 | 0.71 |
| QLQ‐C30 | |||
| Global quality of life | 52 | 0.14 | 0.32 |
| Functional Scales | |||
| Physical functioning | 52 | 0.23 | 0.10 |
| Role functioning | 52 | 0.37 | 0.01 |
| Emotional functioning | 52 | 0.19 | 0.17 |
| Cognitive functioning | 52 | 0.14 | 0.32 |
| Social Functioning | 52 | 0.06 | 0.65 |
| Symptom Scales/Items | |||
| Fatigue | 52 | −0.26 | 0.06 |
| Pain | 52 | 0.05 | 0.72 |
| Dyspnoea | 52 | 0.06 | 0.66 |
| Financial difficulties | 51 | −0.16 | 0.26 |
| Diarrhoea | 51 | −0.17 | 0.24 |
| Constipation | 51 | 0.00 | 0.98 |
| Appetite loss | 52 | 0.15 | 0.31 |
| Insomnia | 52 | 0.07 | 0.63 |
| QLQ‐PR25 | |||
| Functional scales | |||
| Sexual activity | 52 | 0.26 | 0.06 |
| Sexual functioning | 19 | 0.15 | 0.55 |
| Symptom scales/items | |||
| Urinary symptoms | 52 | 0.14 | 0.32 |
| Bowel symptoms | 52 | −0.08 | 0.59 |
| Hormonal symptoms | 52 | −0.31 | 0.03 |
| Incontinence aid | 16 | 0.07 | 0.80 |
|
|
|
| |
| Physical Activity | |||
| ≥150 min per week | 52 | −.585 | 0.56 |
Items were conditional on being sexually active.
Item conditional on requiring an incontinence aid.
Cohen's d = −0.172.
Demographic and clinical characteristics associations with adherence: univariate analyses
|
|
|
| |
|---|---|---|---|
| Comorbidities | 49 | −0.08 | 0.58 |
| Age | 52 | −0.01 | 0.92 |
| Body mass index (BMI) | 51 | −0.11 | 0.45 |
| Weeks since treatment completion | 52 | −0.10 | 0.48 |
| Cancer Stage | 40 | 0.088 | 0.59 |
|
|
|
| |
| Relationship status | 52 | 0.32 | 0.75 |
| Surgery or radiotherapy | 52 | −1.62 | 0.11 |
| ADT treatment | 52 | 1.62 | 0.12 |
| Education | 52 | −2.65 | 0.01 |
Cohen's d effect sizes:
relationship status: 0.130;
Surgery or radiotherapy −0.497;
Androgen deprivation therapy (ADT) treatment = 0.614;
education = −0.60.
Gee model of quality of life factors on adherence to the exercise program
| 95% CI | |||||
|---|---|---|---|---|---|
| B | z |
| Lower | Upper | |
| Model | |||||
| Role functioning | 0.309 | 2.34 | 0.019 | 0.051 | 0.568 |
| Hormonal symptoms | −0.483 | −1.92 | 0.054 | −.976 | .009 |